PET/CT-biomarkers enable risk stratification of patients with relapsed/refractory diffuse large B-cell lymphoma enrolled in the LOTIS-2 clinical trial.
Juan Pablo AlderuccioIsildinha M ReisMehdi HamadaniMuthiah NachiappanSalman LeslomBrad S KahlWeiyun Z AiJohn RadfordMelham M SolhKirit M ArdeshnaBrian T HessMatthew A LunningPier Luigi Luigi ZinzaniAnastasios StathisCarmello Carlo-StellaIzidore S LossosPaolo F CaimiSunwoo HanFei YangRuss A KukerCraig H MoskowitzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Pretreatment MTV demonstrated robust risk-stratification, with those patients demonstrating high-MTV achieving lower responses and survival to loncastuximab tesirine in relapsed/refractory DLBCL.
Keyphrases
- diffuse large b cell lymphoma
- pet ct
- epstein barr virus
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute myeloid leukemia
- prognostic factors
- multiple myeloma
- positron emission tomography
- peritoneal dialysis
- hodgkin lymphoma
- computed tomography
- phase ii
- patient reported outcomes
- double blind
- open label
- study protocol
- free survival
- phase iii